Langerhans cell histiocytosis.
Carlos Rodriguez-Galindo, Carl E Allen
https://pubmed.ncbi.nlm.nih.gov/32106306/Actively Recruiting
Led by West China Second University Hospital · Updated on 2026-01-27
62
Participants Needed
11
Research Sites
N/A
Total Duration
Langerhans cell histiocytosis LCH is the most common histiocytic disorder in children, affecting 2.6 to 8.9 per million annually. It can vary greatly, with some cases improving without treatment. However, when LCH involves special bones like the skull base, temporal bone, eye socket, or spine, or when multiple bone lesions are present in one system, children face higher risks of complications and disease return. Standard treatment involves chemotherapy with vinblastine and prednisone, but many children still experience relapse or long-term nerve problems. Recent discoveries showed overactive MAPK pathways in LCH cells, leading to new treatment approaches with MAPK inhibitors. Luvometinib FCN-159 is a new MAPK inhibitor approved in 2025 for adult LCH treatment. This trial studies luvometinib as a once-daily oral pill in children with single-system special-site single or multifocal bone LCH. The drug was found well tolerated with mild side effects in adults, and compared to chemotherapy, it may offer fewer side effects and allow children to maintain normal life and school without hospital stays or intravenous lines. Children in this study will take 5 mgm of luvometinib orally once daily for one year. Participants will be monitored for event-free survival over two years, with assessments including response rates at 1 and 3 months, overall survival, safety over one year, quality of life, and satisfaction with treatment from before therapy through 12 months. This open-label, single-arm study will follow children closely to evaluate outcomes and potential benefits of luvometinib monotherapy in treating this special-site bone LCH, aiming to provide an easier and potentially more effective treatment option for affected children.
CONDITIONS
Luvometinib in Pediatric SS-LCH With Special-site Single/Multifocal Bone Lesions
X
Xue Tang
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
West China Second University Hospital
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 year
Participants receive luvometinib orally once daily as active treatment for their condition.
Visits at baseline, 1 month, 3 months, 6 months, and 12 months for assessments
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Carlos Rodriguez-Galindo, Carl E Allen
https://pubmed.ncbi.nlm.nih.gov/32106306/Susan J Keam
https://pubmed.ncbi.nlm.nih.gov/40751881/Eli L Diamond, Jean-Francois Emile, Takeshi Fujino...
https://pubmed.ncbi.nlm.nih.gov/41135521/Akira Morimoto, Yoko Shioda, Toshihiko Imamura...
https://pubmed.ncbi.nlm.nih.gov/29594922/Meng Su, Yi-Jin Gao, Ci Pan...
https://pubmed.ncbi.nlm.nih.gov/30693828/James A Whitlock, Birgit Geoerger, Ira J Dunkel...
https://pubmed.ncbi.nlm.nih.gov/36884302/Howard Lin, Akanksha Batajoo, Erin Peckham-Gregory...
https://pubmed.ncbi.nlm.nih.gov/40167581/Xin-Xin Cao, Qi Zhu, Zhen Cai...
https://pubmed.ncbi.nlm.nih.gov/41035796/Riccardo Haupt, Milen Minkov, Itziar Astigarraga...
https://pubmed.ncbi.nlm.nih.gov/23109216/Eily Cournoyer, Justin Ferrell, Susan Sharp...
https://pubmed.ncbi.nlm.nih.gov/37731389/West China Second University Hospital
Lead Sponsor